Alzheimer’s disease (AD), the prevalent dementia in the elderly, involves many related and interdependent pathologies that manifests simultaneously, eventually leading to cognitive impairment and death. No treatment is currently available; however, an agent addressing several key pathologies simultaneously has a better therapeutic potential. Human serum albumin (HSA) is a highly versatile protein, harboring multifunctional properties that are relevant to key pathologies underlying AD. This study provides insight into the mechanism for HSA’s therapeutic effect. In vivo, a myriad of beneficial effects were observed by pumps infusing HSA intracerebroventricularly, for the first time in an AD 3xTg mice model. A significant effect on amyloid-β (Aβ) pathology was observed. Aβ1-42, soluble oligomers, and total plaque area were reduced. Neuroblastoma SHSY5Y cell line confirmed that the reduction in Aβ1-42 toxicity was due to direct binding rather than other properties of HSA. Total and hyperphosphorylated tau were reduced along with an increase in tubulin, suggesting increased microtubule stability. HSA treatment also reduced brain inflammation, affecting both astrocytes and microglia markers. Finally, evidence for blood-brain barrier and myelin integrity repair was observed. These multidimensional beneficial effects of intracranial administrated HSA, together or individually, contributed to an improvement in cognitive tests, suggesting a non-immune or Aβ efflux dependent means for treating AD.
WhiteAR, MulthaupG, MaherF, BellinghamS, CamakarisJ, ZhengH, BushAI, BeyreutherK, MastersCL, CappaiR (1999) The Alzheimer’s disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci19, 9170–9179.
6.
MulthaupG, SchlicksuppA, HesseL, BeherD, RuppertT, MastersCL, BeyreutherK (1996) The amyloid precursor protein of Alzheimer’s disease in the reduction of copper(II) to copper(I). Science271, 1406–1409.
7.
BowmanGL, KayeJA, QuinnJF (2012) Dyslipidemia and blood-brain barrier integrity in Alzheimer’s disease. Curr Gerontol Geriatr Res2012, 184042.
ZunszainPA, GhumanJ, McDonaghAF, CurryS (2008) Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. J Mol Biol381, 394–406.
10.
ZoellnerH, HouJY, LoveryM, KinghamJ, SrivastavaM, BielekE, VanyekE, BinderBR (1999) Inhibition of microvascular endothelial apoptosis in tissue explants by serum albumin. Microvasc Res57, 162–173.
11.
GaleazziL, GaleazziR, ValliMB, CorderEH, GiuntaS (2002) Albumin protects human red blood cells against Abeta25-35-induced lysis more effectively than ApoE. Neuroreport13, 2149–2154.
12.
OnalC, UnalF, TurantanMI, UzümG, HasanoğluA, KaynarMY (1997) The effect of inttricular albumin in experimental brain oedema. Acta Neurochir (Wien)139, 661–668. discussion 668-669.
13.
BelayevL, LiuY, ZhaoW, BustoR, GinsbergMD (2001) Human albumin therapy of acute ischemic stroke: Marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke32, 553–560.
14.
TaberneroA, GrandaB, MedinaA, Sánchez-AbarcaLI, LavadoE, MedinaJM (2002) Albumin promotes neuronal survival by increasing the synthesis and release of glutamate. J Neurochem81, 881–891.
15.
GumET, SwansonRA, AlanoC, LiuJ, HongS, WeinsteinPR, PanterSS (2004) Human serum albumin and its N-terminal tetrapeptide (DAHK) block oxidant-induced neuronal death. Stroke35, 590–595.
16.
VeeringBT, BurmAG, SouverijnJH, SerreeJM, SpierdijkJ (1990) The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein. Br J Clin Pharmacol29, 201–206.
17.
LlewellynDJ, LangaKM, FriedlandRP, LangIA (2010) Serum albumin concentration and cognitive impairment. Curr Alzheimer Res7, 91–96.
18.
WisniewskiHM, KozlowskiPB (1982) Evidence for blood-brain barrier changes in senile dementia of the Alzheimer type (SDAT). Ann N Y Acad Sci396, 119–129.
19.
KuoYM, KokjohnTA, KalbackW, LuehrsD, GalaskoDR, ChevallierN, KooEH, EmmerlingMR, RoherAE (2000) Amyloid-beta peptides interact with plasma proteins and erythrocytes: Implications for their quantitation in plasma. Biochem Biophys Res Commun268, 750–756.
20.
MilojevicJ, MelaciniG (2011) Stoichiometry and affinity of the human serum albumin-Alzheimer’s Aβ peptide interactions. Biophys J100, 183–192.
21.
BiereAL, OstaszewskiB, StimsonER, HymanBT, MaggioJE, SelkoeDJ (1996) Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem271, 32916–32922.
22.
YamamotoK, ShimadaH, KohH, AtakaS, MikiT (2014) Serum levels of albumin-amyloid beta complexes are decreased in Alzheimer’s disease. Geriatr Gerontol Int14, 716–723.
23.
MilojevicJ, RaditsisA, MelaciniG (2009) Human serum albumin inhibits Abeta fibrillization through a “monomer-competitor” mechanism. Biophys J97, 2585–2594.
24.
OddoS, CaccamoA, ShepherdJD, MurphyMP, GoldeTE, KayedR, MetherateR, MattsonMP, AkbariY, LaferlaFM (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular A(and synaptic dysfunction. Neuron39, 409–421.
25.
BelinsonH, LevD, MasliahE, MichaelsonDM (2008) Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. J Neurosci28, 4690–4701.
26.
AvrahamiL, FarfaraD, Shaham-KolM, VassarR, FrenkelD, Eldar-FinkelmanH (2013) Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: In vivo and in vitro studies. J Biol Chem288, 1295–1306.
27.
SauraCA, ChenG, MalkaniS, ChoiS-Y, TakahashiRH, ZhangD, GourasGK, KirkwoodA, MorrisRGM, ShenJ (2005) Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci25, 6755–6764.
28.
LarsonME, LesnéSE (2012) Soluble Aβ oligomer production and toxicity. J Neurochem120(Suppl), 125–139.
29.
WalshDM, SelkoeDJ (2007) A beta oligomers - a decade of discovery. J Neurochem101, 1172–1184.
30.
Reyes BarceloAA, Gonzalez-VelasquezFJ, MossMA (2009) Soluble aggregates of the amyloid-beta peptide are trapped by serum albumin to enhance amyloid-beta activation of endothelial cells. J Biol Eng3, 5.
31.
AlgamalM, MilojevicJ, JafariN, ZhangW, MelaciniG (2013) Mapping the Interactions between the Alzheimer’s Aβ-peptide and human serum albumin beyond domain resolution. Biophys J105, 1700–1709.
32.
ReeseLC, ZhangWR, DineleyKT, KayedR, TaglialatelaG (2008) Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell7, 824–835.
33.
DemuroA, MinaE, KayedR, MiltonSC, ParkerI, GlabeCG (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem280, 17294–17300.
34.
FilaliM, LalondeR, TheriaultP, JulienC, CalonF, PlanelE (2012) Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer’s disease expressing mutated APP, PS1, and Mapt (3xTg-AD). Behav Brain Res234, 334–342.
35.
StoverKR, CampbellMA, Van WinssenCM, BrownRE (2015) Early detection of cognitive deficits in the 3xTg-AD mouse model of Alzheimer’s disease. Behav Brain Res289, 29–38.
StanyonHF, VilesJH (2012) Human serum albumin can regulate amyloid-β peptide fiber growth in the brain interstitium: Implications for Alzheimer disease. J Biol Chem287, 28163–28168.
38.
Rabinovich-NikitinI, RakoverIS, BeckerM, SolomonB (2012) Beneficial effect of antibodies against β- secretase cleavage site of APP on Alzheimer’s-like pathology in triple-transgenic mice. PLoS One7, e46650.
39.
OhK-J, PerezSE, LagalwarS, VanaL, BinderL, MufsonEJ (2010) Staging of Alzheimer’s pathology in triple transgenic mice: A light and electron microscopic analysis. Int J Alzheimers Dis2010, pii: 780102.
40.
OtvosL, FeinerL, LangE, SzendreiGI, GoedertM, LeeVM (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res39, 669–673.
41.
BeachTG, WalkerR, McgeerEG (1989) Patterns of gliosis in Alzheimer’s disease and aging cerebrum. Glia2, 420–436.
42.
Vartak-SharmaN, GhorpadeA (2012) Astrocyte elevated gene-1 regulates astrocyte responses to neural injury:Implications for reactive astrogliosis and neurodegeneration. J Neuroinflammation9, 195.
CarranoA, HoozemansJJM, van der ViesSM, van HorssenJ, de VriesHE, RozemullerAJM (2012) Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy. Neurodegener Dis10, 329–331.
46.
DesaiMK, SudolKL, JanelsinsMC, MastrangeloMA, FrazerME, BowersWJ (2009) Triple-transgenic Alzheimer’s disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia57, 54–65.
47.
BehrendtG, BaerK, BuffoA, CurtisMA, FaullRL, ReesMI, GötzM, DimouL (2013) Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia61, 273–286.
48.
DesaiMK, MastrangeloMA, RyanDA, SudolKL, NarrowWC, BowersWJ (2010) Early oligodendrocyte/myelin pathology in Alzheimer’s disease mice constitutes a novel therapeutic target. Am J Pathol177, 1422–1435.
49.
SmallDH, MokSS, BornsteinJC (2001) Alzheimer’s disease and Abeta toxicity: From top to bottom. Nat Rev Neurosci2, 595–598.
50.
KirkitadzeMD, BitanG, TeplowDB (2002) Paradigm shifts in Alzheimer’s disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. J Neurosci Res69, 567–577.
51.
WilliamsTL, SerpellLC (2011) Membrane and surface interactions of Alzheimer’s Aβ peptide–insights into the mechanism of cytotoxicity. FEBS J278, 3905–3917.
52.
Ferreira ST, Vieira MNN, De Felice. FG Soluble protein oligomers as emerging toxins in Alzheimer’s and other amyloid diseases. IUBMB Life59, 332–345.
53.
MakridesV, ShenTE, BhatiaR, SmithBL, ThimmJ, LalR, FeinsteinSC (2003) Microtubule-dependent oligomerization of tau. Implications for physiological tau function and tauopathies. J Biol Chem278, 33298–33304.
54.
GendronTF, PetrucelliL (2009) The role of tau in neurodegeneration. Mol Neurodegener4, 13.
55.
ChabrierMA, Blurton-JonesM, AgazaryanAA, NerhusJL, Martinez-CoriaH, LaFerlaFM (2012) Soluble Aβ promotes wild-type tau pathology in vivo. J Neurosci32, 17345–17350.
56.
LueLF, RydelR, BrighamEF, YangLB, HampelH, MurphyGM, BrachovaL, Du YanS, WalkerDG, ShenY, RogersJ (2001) Inflammatory repertoire of Alzheimer’s disease and nondemented elderly microglia in vitro. Glia35, 72–79.
57.
EricksonMA, BanksWA (2013) Blood-brain barrier dysfunction as a cause and consequence of Alzheimer’s disease. J Cereb Blood Flow Metab33, 1500–1513.
58.
De La TorreJC (2004) Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol3, 184–190.
59.
BrkicM, BalusuXS, WonterghemE, Van GorleN, BenilovaI, KremerA, Van HoveI, MoonsL, De StrooperB, KanazirS, LibertC, VandenbrouckeXRE (2015) Amyloid (oligomers disrupt blood – CSF barrier integrity by activating matrix metalloproteinases. J Neurosci35, 12766–12778.
60.
TakedaS, SatoN, IkimuraK, NishinoH, RakugiH, MorishitaR (2013) Increased blood-brain barrier vulnerability to systemic inflammation in an Alzheimer disease mouse model. Neurobiol Aging34, 2064–2070.
KotarbaAE, AucoinD, HoosMD, SmithSO, Van NostrandWE (2013) Fine mapping of the amyloid β-protein binding site on myelin basic protein. Biochemistry52, 2565–2573.
63.
LiaoM-C, HoosMD, AucoinD, AhmedM, DavisJ, SmithSO, Van NostrandWE (2010) N-terminal domain of myelin basic protein inhibits amyloid beta-protein fibril assembly. J. Biol. Chem285, 35590–35598.
64.
ClarnerT, DiederichsF, BergerK, DeneckeB, GanL, van der ValkP, BeyerC, AmorS, KippM (2012) Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions. Glia60, 1468–1480.
65.
BogieJF, JorissenW, MailleuxJ, NijlandPG, ZelcerN, VanmierloT, Van HorssenJ, StinissenP, HellingsN, HendriksJJ (2013) Myelin alters the inflammatory phenotype of macrophages by activating PPARs. Acta Neuropathol Commun1, 43.
66.
BaltanásFC, WeruagaE, ValeroJ, RecioJS, AlonsoJR (2009) Albumin attenuates DNA damage in primary-cultured neurons. Neurosci Lett450, 23–26.
67.
BoadaM, OrtizP, AnayaF, HernándezI, MuñozJ, NúñezL, OlazaránJ, RocaI, CuberasG, TárragaL, BuendiaM, PlaRP, FerrerI, PáezA (2009) Amyloid-targeted therapeutics in Alzheimer’s disease: Use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect22, 325–339.
68.
PascaleCL, MillerMC, ChiuC, BoylanM, CaralopoulosIN, GonzalezL, JohansonCE, SilverbergGD (2011) Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. Fluids Barriers CNS8, 21.
69.
ShibataM, YamadaS, KumarSR, CaleroM, BadingJ, FrangioneB, HoltzmanDM, MillerCA, StricklandDK, GhisoJ, ZlokovicBV (2000) Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest106, 1489–1499.
70.
MawuenyegaKG, SigurdsonW, OvodV, MunsellL, KastenT, MorrisJC, YarasheskiKE, BatemanRJ (2010) Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science330, 2010.
71.
LemereCA (2013) Immunotherapy for Alzheimer’s disease: Hoops and hurdles. Mol Neurodegener8, 36.
